CA3015309C - Composes de carbapeneme - Google Patents

Composes de carbapeneme Download PDF

Info

Publication number
CA3015309C
CA3015309C CA3015309A CA3015309A CA3015309C CA 3015309 C CA3015309 C CA 3015309C CA 3015309 A CA3015309 A CA 3015309A CA 3015309 A CA3015309 A CA 3015309A CA 3015309 C CA3015309 C CA 3015309C
Authority
CA
Canada
Prior art keywords
optionally substituted
date
cooh
substituted
f2hc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3015309A
Other languages
English (en)
Other versions
CA3015309A1 (fr
Inventor
Gopalan Balasubramanian
Maneesh Paul-Satyaseela
Chidambaram Venkateswaran Srinivasan
Sridhar Ramanathan Iyer
Hariharan Periasamy
Venkatesan Parameswaran
Bharani THIRUNAVUKKARASU
Prabhakar Rao Gunturu
Manjula Devi Deshkumar
Venkateshwarlu JAKKALA
Ravi Nargund
Michael Wayne Miller
Sheo Singh
Shuzhi DONG
Hongwu Wang
Katherine Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orchid Pharma Ltd
Merck Sharp and Dohme LLC
Original Assignee
Orchid Pharma Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Pharma Ltd, Merck Sharp and Dohme LLC filed Critical Orchid Pharma Ltd
Publication of CA3015309A1 publication Critical patent/CA3015309A1/fr
Application granted granted Critical
Publication of CA3015309C publication Critical patent/CA3015309C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La présente invention concerne des composés de carbapénème, leurs stéréoisomères, et leurs sels ou N-oxydes pharmaceutiquement acceptables, qui peuvent être utiles pour traiter les infections bactériennes, en particulier les infections bactériennes pharmacorésistantes, ainsi que des procédés de préparation des composés, des compositions pharmaceutiques de ces composés et leur utilisation dans le traitement d'une infection bactérienne.
CA3015309A 2016-03-16 2017-03-15 Composes de carbapeneme Active CA3015309C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201641009127 2016-03-16
IN201641009127 2016-03-16
PCT/IN2017/000060 WO2017158616A1 (fr) 2016-03-16 2017-03-15 Composés de carbapénème

Publications (2)

Publication Number Publication Date
CA3015309A1 CA3015309A1 (fr) 2017-09-21
CA3015309C true CA3015309C (fr) 2024-02-13

Family

ID=58715155

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3015309A Active CA3015309C (fr) 2016-03-16 2017-03-15 Composes de carbapeneme

Country Status (12)

Country Link
US (1) US11180504B2 (fr)
EP (1) EP3430013B1 (fr)
JP (1) JP7213173B2 (fr)
KR (1) KR102435777B1 (fr)
CN (1) CN109415365B (fr)
AU (1) AU2017235293B2 (fr)
CA (1) CA3015309C (fr)
IL (1) IL261782B2 (fr)
MA (1) MA43791A (fr)
MX (1) MX382439B (fr)
WO (1) WO2017158616A1 (fr)
ZA (1) ZA201805158B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102288736B1 (ko) 2018-08-03 2021-08-12 한양대학교 에리카산학협력단 카바페넴 내성 박테리아 검출용 프로브 및 이의 용도
WO2020027553A1 (fr) * 2018-08-03 2020-02-06 한양대학교 에리카산학협력단 Sonde pour la détection de bactéries résistantes au carbapénème et utilisation correspondante
WO2023007325A1 (fr) * 2021-07-28 2023-02-02 University Of Kwazulu-Natal INHIBITEURS DE MÉTALLO-β-LACTAMASES
CN119317620A (zh) 2022-06-13 2025-01-14 亚力维克希斯股份有限公司 氮杂环烷基羰基环状胺化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
EP0082133A3 (en) 1979-04-19 1983-07-20 Merck & Co. Inc. A process for preparing intermediates useful for preparing 2-substituted-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids
EP0044170A1 (fr) 1980-07-11 1982-01-20 Beecham Group Plc Antibiotiques bêta-lactame, leur préparation et leur utilisation
JPS57158785A (en) 1981-02-27 1982-09-30 Beecham Group Ltd Beta-lactam antibiotic, manufacture and medicinal composition
EP0059554A3 (fr) 1981-02-27 1982-10-20 Beecham Group Plc Antibiotiques bêta-lactame, un procédé pour leur préparation et leur application en compositions pharmaceutiques
CA1283906C (fr) * 1983-05-09 1991-05-07 Makoto Sunagawa COMPOSE DE .beta.-LACTAM ET PROCEDE DE PRODUCTION
JPS60233076A (ja) * 1984-05-03 1985-11-19 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
JPS6383062A (ja) * 1986-09-26 1988-04-13 Nippon Redarii Kk アゼチジンスルホン酸誘導体
CA2004798A1 (fr) * 1988-12-09 1990-06-09 Jacques Banville 6-aminoalkyl carbapenemes
JPH04211083A (ja) * 1990-02-23 1992-08-03 Sankyo Co Ltd カルバペネム−3−カルボン酸誘導体
JP2934283B2 (ja) * 1990-05-29 1999-08-16 第一製薬株式会社 カルバペネム誘導体
IL102093A (en) 1991-06-04 1996-12-05 Sankyo Co 1-methylcarbapenem derivatives process for the preparation thereof and pharmaceutical compositions containing the same
US5317016A (en) * 1991-08-20 1994-05-31 Shionogi Seiyaku Kabushiki Kaisha Pyrrolidylthiocarbapenem derivative
GB9202298D0 (en) 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
JP3411589B2 (ja) * 1992-05-11 2003-06-03 第一製薬株式会社 カルバペネム誘導体
US5602118A (en) 1993-03-16 1997-02-11 American Cyanamid Company 2-thiosubstituted carbapenems
JP3199300B2 (ja) 1994-05-09 2001-08-13 三共株式会社 1−メチルカルバペネム誘導体

Also Published As

Publication number Publication date
MA43791A (fr) 2018-11-28
WO2017158616A8 (fr) 2018-06-07
IL261782A (en) 2018-10-31
CN109415365B (zh) 2022-08-09
AU2017235293A1 (en) 2018-08-23
RU2018136064A3 (fr) 2020-04-16
EP3430013B1 (fr) 2023-11-15
CN109415365A (zh) 2019-03-01
KR102435777B1 (ko) 2022-08-23
MX382439B (es) 2025-03-13
IL261782B2 (en) 2024-07-01
JP7213173B2 (ja) 2023-01-26
IL261782B1 (en) 2024-03-01
MX2018011095A (es) 2019-01-10
RU2018136064A (ru) 2020-04-16
AU2017235293B2 (en) 2021-02-04
US11180504B2 (en) 2021-11-23
KR20180133420A (ko) 2018-12-14
ZA201805158B (en) 2023-01-25
EP3430013A1 (fr) 2019-01-23
WO2017158616A1 (fr) 2017-09-21
US20200291029A1 (en) 2020-09-17
JP2019512547A (ja) 2019-05-16
CA3015309A1 (fr) 2017-09-21
BR112018068462A2 (pt) 2019-01-22

Similar Documents

Publication Publication Date Title
AU2023200842B2 (en) 3-carbonylamino-5-cyclopentyl-1H-pyrazole compounds having inhibitory activity on CDK2
AU2021203373B2 (en) MCL-1 inhibitors
ES2939775T3 (es) Macrociclos como moduladores del regulador de la conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de los mismos, su uso en el tratamiento de la fibrosis quística, y procesos para elaborarlos
AU2018306606B2 (en) Compounds and methods for the targeted degradation of Androgen Receptor
AU2003235741B8 (en) Deazapurines and uses thereof
CA3015309C (fr) Composes de carbapeneme
CA3078195A1 (fr) Nouveaux composes de sulfonamide carboxamide
AU2023248127A1 (en) Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
US20210130329A1 (en) Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
EP3125895A1 (fr) Inhibiteurs spirocycliques substitués de l'autotaxine
TW202136239A (zh) 用於治療與sting活性相關之病狀的化合物及組合物
UA126000C2 (uk) Хроманмонобактамові сполуки для лікування бактеріальних інфекцій
KR20210049895A (ko) 고 활성 sting 단백질 작용제 화합물
ES2944658T3 (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de PI3Kdelta
ES2740224T3 (es) 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
UA129150C2 (uk) Оксозаміщена сполука
KR20240056718A (ko) Sting 활성과 연합된 상태를 치료하기 위한 화합물 및 조성물
HU191066B (en) Process for preparing carbapenem derivatives
AU643735B2 (en) 4-substituted alkyl carbapenem antibiotics
RU2772909C2 (ru) Карбапенемовые соединения
JPS58198487A (ja) カルバペネム抗生物質
NZ709355A (en) New bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314